Bone Disorder

Older women with chronic kidney disease who take denosumab may have a higher risk for emergently treated hypocalcemia compared with those treated with bisphosphonates, according to published data.

Changes in body composition may correlate with bone mineral density fluctuations in non-dialysis-dependent chronic kidney disease, according to a cohort study.

Diabetes mellitus may modify the link between chronic kidney disease-mineral and bone disorder biomarkers and aortic stiffness in adults on peritoneal dialysis, according to recently published data.

A meta-analysis of randomized controlled trials suggested magnesium supplementation alone might benefit patients on hemodialysis with chronic kidney disease-mineral bone disorder.

Evaluating bone mineral density can help predict atherosclerotic CVD events in women, according to a study published in Heart.

Patients with both X-linked hypophosphatemia and tumor-induced osteomalacia can benefit from phosphorus replacement therapy, according to two presentations at the United Rheumatology Spring Virtual conference.

Chronic kidney disease-mineral bone disorder is a systemic disorder prevalent among individuals with advanced chronic kidney disease and end-stage kidney disease.

An international team of researchers has identified key clinical features of chronic nonbacterial osteomyelitis to help develop vital classification criteria.

The saying “April showers bring May flowers” has taken on a different meaning this year. We are getting showers of statistics, updates, policies, guidelines and change. More than ever, we are wishing for those May flowers.

Researchers found differences for levels of parathyroid hormone, calcium and phosphorus in the first 5 years of hemodialysis based on patient race and country of origin.